At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 18 enrolled
Drug / intervention
Imatinib Mesylate 400Mg Capsule +1 moredrug
Likely dose
Imatinib mesylate 400 mg dailyAI-extracted
Key inclusion· 2
- ✓Definite or Probable LAM diagnosis
- ✓FVC or Postbronchodilator FEV1 <90% predicted
Key exclusion· 9
- ✕Current or planned pregnancy or lactation
- ✕Unwillingness to discontinue sirolimus
- ✕Change in sirolimus dose or use within the past month
- ✕Current cigarette smoking
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
LAM Pilot Study With Imatinib Mesylate
In Brief
A Phase 2 clinical trial evaluating Imatinib Mesylate 400Mg Capsule and Placebo - Capsule for Lymphangioleiomyomatosis. Completed, enrolled 18 participants across 2 sites.
Detailed Summary
This is a phase 1 clinical trial comparing imatinib mesylate to placebo for individuals with lymphangioleiomyomatosis (LAM).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLymphangioleiomyomatosis
CountriesUnited States
CollaboratorsColumbia University
Timeline
Phase 2CompletedFinished
201820192020202120222023202420252026
First PostedApr 2017
Enrollment StartJan 2018
Primary CompletionMar 2019
TodayJul 2026
First PostedApr 27, 2017
Enrollment StartJan 23, 2018
Primary CompletionMar 7, 2019
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 9.2 years ago
Interventions
Imatinib Mesylate 400Mg Capsuledrug
Sirolimus or everolimus will be withdrawn after 28 days if used at baseline
Placebo - Capsuledrug
Sirolimus or everolimus will be withdrawn after 28 days if used at baseline